SCHEMBL5404593

SCHEMBL5404593

Cc1ccc(Oc2c3ccccc3c(Oc3ccc(C)cc3)c3ccccc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KMT2A Q03164 6/20 0.48
MAPT P10636 4/20 0.48
KDM4E B2RXH2 2/20 0.48
GLA P06280 1/20 0.48
TEAD4 Q15561 1/20 0.48
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 4/20 0.47
LMNA P02545 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KDM1A O60341 1/20 0.46
MAPK1 P28482 1/20 0.44
ACHE P22303 1/20 0.44
HTR2A P28223 2/20 0.43
SLC6A4 P31645 2/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31008769 1.00 HTT (0.49) HTTSMN1; SMN2KMT2AMAPTKDM4E
SCHEMBL30863325 0.84 KMT2A (0.75) HTTSMN1; SMN2KMT2AMAPTKDM4E
SCHEMBL3874015 0.82 TEAD4 (0.59) HTTSMN1; SMN2KMT2AMAPTKDM4E
SCHEMBL31081024 0.81 KMT2A (0.50) HTTSMN1; SMN2KMT2AMAPTKDM4E
SCHEMBL4898172 0.79 KDM4E (0.70) HTTSMN1; SMN2KMT2AMAPTKDM4E
SCHEMBL30003990 0.79 KDM4E (0.70) HTTSMN1; SMN2KMT2AMAPTKDM4E
SCHEMBL16920392 0.79 KDM4E (0.57) HTTSMN1; SMN2KMT2AMAPTKDM4E
SCHEMBL425356 0.77 HTT (0.69) HTTSMN1; SMN2KMT2AMAPTTEAD4
SCHEMBL12355 0.77 HTT (0.69) HTTSMN1; SMN2KMT2AMAPTTEAD4
SCHEMBL17081753 0.77 HTT (0.69) HTTSMN1; SMN2KMT2AMAPTTEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1574493-B1 PROCESS FOR PRODUCING ANTHRACENE DIETHER KAWASAKI KASEI CHEMICALS (JP) 2013-06-19 EP disclosed
US-7279607-B2 Process for producing anthracene diether KAWASAKI KASEI CHEMICALS LTD. (JP) 2007-10-09 US disclosed
US-20060079721-A1 Process for producing anthracene diether HIROYUKI HONDA ET EL 2006-04-13 US disclosed
EP-1574493-A1 PROCESS FOR PRODUCING ANTHRACENE DIETHER Kawasaki Kasei Chemicals Ltd. (JP) 2005-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079721-A1 Process for producing anthracene diether DOHH, DHCR7, HSD17B11 HTT 2263/4885SMN1; SMN2 4406/4885KMT2A 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.